• A phase 3 trial examining Novo Nordisk's (NVO) GLP-1 medicine semaglutide as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) met its primary endpoints.
• Those endpoints were significant improvement in liver fibrosis with no worsening of steatohepatitis, and no worsening of liver fibrosis in those with MASH compared to placebo.
• In the study, 2.4 mg semaglutide was given subcutaneously once a week.
• Results from part 1 of the ESSENCE trial showed that at week 72, 62.9% of people treated with semaglutide achieved resolution of steatohepatitis with no worsening of liver fibrosis compared to 34.1% on placebo. Also, 37% of people treated with semaglutide 2.4 mg achieved improvements in liver fibrosis with no worsening of steatohepatitis compared to 22.5% on placebo.
• A secondary endpoint found 32.8% of those on semaglutide 2.4 mg achieved both resolution of steatohepatitis with improvements in liver fibrosis vs. 16.2% of placebo patients.
• Semaglutide is also sold by Novo as a type 2 diabetes medicine under the name Ozempic and as a weight loss treatment called Wegovy.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.